These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26238980)

  • 21. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
    J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
    Venkatraman S; Velazquez F; Wu W; Blackman M; Madison V; Njoroge FG
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2151-5. PubMed ID: 20226659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.
    Lampa A; Ehrenberg AE; Vema A; Åkerblom E; Lindeberg G; Danielson UH; Karlén A; Sandström A
    Bioorg Med Chem; 2011 Aug; 19(16):4917-27. PubMed ID: 21782454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors.
    Chung V; Carroll AR; Gray NM; Parry NR; Thommes PA; Viner KC; D'Souza EA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1381-90. PubMed ID: 15793116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease.
    Ontoria JM; Di Marco S; Conte I; Di Francesco ME; Gardelli C; Koch U; Matassa VG; Poma M; Steinkühler C; Volpari C; Harper S
    J Med Chem; 2004 Dec; 47(26):6443-6. PubMed ID: 15588076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
    Xue W; Wang M; Jin X; Liu H; Yao X
    Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
    Li X; Liu Y; Zhang YK; Plattner JJ; Baker SJ; Bu W; Liu L; Zhou Y; Ding CZ; Zhang S; Kazmierski WM; Hamatake R; Duan M; Wright LL; Smith GK; Jarvest RL; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Wang A
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7351-6. PubMed ID: 23142614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
    Ortqvist P; Peterson SD; Kerblom E; Gossas T; Sabnis YA; Fransson R; Lindeberg G; Helena Danielson U; Karlén A; Sandström A
    Bioorg Med Chem; 2007 Feb; 15(3):1448-74. PubMed ID: 17113777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA; Perni RB
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
    Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
    Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
    Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
    Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
    J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
    Hamill P; Jean F
    Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.
    Lei YF; Yin W; Yang J; Lv X; Wei SH; An QX; Hu XB; Xu ZK
    Acta Virol; 2008; 52(3):133-41. PubMed ID: 18999887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.
    Takaya D; Yamashita A; Kamijo K; Gomi J; Ito M; Maekawa S; Enomoto N; Sakamoto N; Watanabe Y; Arai R; Umeyama H; Honma T; Matsumoto T; Yokoyama S
    Bioorg Med Chem; 2011 Nov; 19(22):6892-905. PubMed ID: 21992802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent aza-peptide derived inhibitors of HCV NS3 protease.
    Venkatraman S; Wu W; Shih NY; George Njoroge F
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
    Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.